Skip to main content
Frontiers in Cellular and Infection Microbiology logoLink to Frontiers in Cellular and Infection Microbiology
. 2022 Nov 11;12:1040414. doi: 10.3389/fcimb.2022.1040414

Epidemiology of hand, foot, and mouth disease and the genetic characteristics of Coxsackievirus A16 in Taiyuan, Shanxi, China from 2010 to 2021

Jiane Guo 1,2,, Zijun Cao 1,, Hongyan Liu 1, Jihong Xu 2, Lifeng Zhao 2, Li Gao 2, Zhihong Zuo 2, Yang Song 3, Zhenzhi Han 3, Yong Zhang 3,4,*, Jitao Wang 1,2,*
PMCID: PMC9692002  PMID: 36439232

Abstract

Hand, foot, and mouth disease (HFMD) is a common childhood infectious disease caused by human enteroviruses (EV). This study aimed to describe the epidemiological features of HFMD and the genetic characteristics of Coxsackievirus A16 (CVA16) in Taiyuan, Shanxi, China, from 2010 to 2021. Descriptive epidemiological methods were used to analyze the time and population distribution of HFMD and the genetic characteristics of CVA16. Except being affected by the COVID-19 epidemic in 2020, HFMD epidemics were sporadic from January to March each year, and began to increase in April, with a major epidemic peak from May to August, which declined in September, followed by a secondary peak from October to December. The prevalence of EV infection was the highest in children aged one to five years (84.42%), whereas its incidence was very low in children under one year of age (5.48%). Enterovirus nucleic acid was detected by real-time reverse transcription polymerase chain reaction in 6641 clinical specimens collected from patients with HFMD from 2010 to 2021, and 4236 EV-positive specimens were detected, including 988 enterovirus A71 (EV-A71), 1488 CVA16, and 1760 other enteroviruses. CVA16 remains prevalent and has co-circulated with other EVs in Taiyuan from 2010 to 2021. A phylogenetic tree constructed based on the VP1 region showed that all CVA16 strains belonged to two different clades of the B1 genotype, B1a and B1b. They showed a nucleotide similarity of 86.5–100%, and an amino acid similarity of 96.9–100%. Overall, these findings add to the global genetic resources of CVA16, demonstrate the epidemiological characteristics of HFMD as well as the genetic features of CVA16 in Taiyuan City during 2010–2021, and provide supporting evidence for the prevention and control of HFMD.

Keywords: hand, foot, and mouth disease, epidemiology, Coxsackievirus A16, genetic characteristics, VP1

Introduction

Hand, foot, and mouth disease (HFMD) was first described in New Zealand in 1957 and is a common childhood infectious illness (Nhu et al., 2021). It is prevalent worldwide and occurs mainly in children under 5 years of age (Xing et al., 2014; Ji et al., 2019). In the past decades, particularly in the Asia-Pacific region, multiple outbreaks of HFMD have been recorded in Singapore, Vietnam, and mainland China (Lim et al., 2016; Cai et al., 2019; Van et al., 2019). After several large HFMD outbreaks during 2007 and early 2008, HFMD was defined as a C-class notifiable communicable disease by the Ministry of Health of China and an HFMD virological surveillance system was set up in 2008 (Zhang et al., 2009; Tian et al., 2014). HFMD is associated with fever and/or typical vesicular rashes on the hands, feet, buttocks, or mouth as the main symptoms. Patients with HFMD mostly develop mild and self-limited symptoms, but may also progress to serious illnesses such as acute flaccid paralysis, encephalitis, myocarditis, and encephalomyelitis (Li et al., 2005; Esposito and Principi, 2018; Yin et al., 2018).

HFMD is caused by human enterovirus (EV), a non-enveloped single positive-stranded RNA virus with a total genome length of about 7.4 kb, which encodes four structural proteins (VP1-VP4); the VP1 region is commonly used for enterovirus genotyping (Noisumdaeng et al., 2019). EVs can be divided into four species (A-D). Most HFMD cases are caused by the species EV-A, which includes two major pathogens, coxsackievirus A16 (CVA16) and enterovirus A71 (EV-A71) (Zhang and Xu, 2013). In recent years, national surveillance of HFMD cases has revealed that the pathogens causing HFMD are constantly changing. After applying the EV-A71 inactivated vaccine marketed in China in 2016, the number of HFMD caused by EV-A71 has decreased rapidly (Hong et al., 2022), whereas the proportion of CVA16 has gradually increased, and the proportion of other EVs in the pathogen spectrum has increased significantly (Chen et al., 2017; He et al., 2018). This indicates that the monovalent EV-A71 inactivated vaccine can prevent 90% of EV-A71-induced HFMD cases, but provides no cross-protection against infection with CVA16 and other EVs (Li et al., 2014; Li et al., 2016; Takahashi et al., 2016), resulting in the consistently high number of CVA16-related HFMD cases.

HFMD, with the exception of Polar regions, is global in distribution (Cox et al., 2017). It has been prevalent since the 1990’s and has subsequently caused large-scale epidemics every few years with notified cases exceeding a million each year (Koh et al., 2018). In China, as of December 2021, the cumulative total number of reported cases reached approximately 24.57 million since HFMD was listed as a notifiable infectious disease in 2008, 3698 of whom died according to the National Health Commission of the People’s Republic of China (http://www.nhc.gov.cn/).

Shanxi Province is located in central China and its capital city, Taiyuan, is located at the center of Shanxi Province. Taiyuan City established a HFMD surveillance system in 2010, but the epidemic and genetic characteristics of CVA16 remain unclear, and especially require continuous surveillance and analysis. To address this problem, we investigated the epidemiology of hand, foot, and mouth disease and the genetic characteristics of Coxsackievirus A16 in Taiyuan, Shanxi, China from 2010 to 2021.

Methods

Case definitions

HFMD case-reporting criteria are defined in the national guidelines for control and prevention for HFMD (issued by Ministry of Health in China (2009)). For clinical diagnosis, HFMD cases include mild and severe cases. Mild cases are defined as fever or not showing fever accompanied by rash (maculopapular or vesicular rash) appearing at the sites of hand, foot, mouth or buttock. Severe cases displayed severe neurological or cardiopulmonary clinical symptoms, such as acute flaccid paralysis, aseptic meningitis and pulmonary hemorrhage.

Epidemiological analysis

The demographic data were obtained from the statistical yearbook of Shanxi Province. The data of HFMD cases in Taiyuan City from January 2010 to December 2021 was obtained from the China Information System for Disease Control and Prevention. The data of the reported cases included the gender, age, and onset of the disease time, which were sorted using Excel software. Statistical analyses were performed to describe epidemiological features, including demographic characteristics, gender and age distribution and seasonal variation. Total incidence was defined as the total number of HFMD cases divided by the average population size during the study period. Data analyses were performed using SPSS Statistics software (Version 26.0). Chi-square was performed on the patients’ demographic categories. Statistical significance was set at P < 0.05.

Specimen collection

Throat swab or stool specimens were collected from clinically diagnosed HFMD cases within three days of onset at the district and county Centers for Disease Control and Prevention (CDC) in Taiyuan City. In total, 6641 specimens were collected during 2010–2021 and sent to the virus microbiology laboratory in Taiyuan CDC for enterovirus nucleic acid detection. Upon receipt at the laboratory, each specimen was assigned a unique laboratory code and entered into the Gastroenteritis Information Database at Taiyuan CDC.

RNA extraction

According to the manufacturer’s instructions, total RNA was extracted from 50 μL of clinical specimens using a MagMax-96 Viral RNA Isolation Kit (Thermo Fisher

Scientific, Foster City, CA). RNA-positive control and negative control (ddH2O) was included in the extraction procedure in each batch. The step of RNA extraction was done in a biosafety cabinet.

EV identification

RNA samples were tested for EV typing using Enterovirus 71 & Coxsackie Virus A16 & Enterovirus Real Time RT-PCR Kit (Shanghai ZJ Bio-Tech Co., Ltd., Shanghai, China) and CFX96™ Real-time PCR Detection System (CFX96, Bio-Rad, Hercules, California, USA).

A 25 μL reaction system comprising 1 μL of enzyme mixture,19 μL of reaction solution, and 5 μL of viral nucleic acid was prepared. PCR cycling parameters were set up according to the manufacturer’s instructions as follows: 50°C for 30 min, 95°C for 10 min, followed by 45 cycles of 95°C for 10 s, and 55°C for 40 s. A positive result was defined as a cycle threshold (Ct) value ≤ 43, and the positive control was defined as a Ct value ≤ 35.

VP1 region amplification and nucleotide sequencing

In total, 362 specimens were randomly selected to amplify the VP1 region with specific primer pairs for CVA16 (upstream primer, CVA16-VP1-S: ATTGGTGCTCCCACTACAGC, and downstream primer, CVA16-VP1-A: GCTGTCCTCCCACACAAGAT) (Zhang et al., 2010). The primers yielded a CVA16 amplification product of 1110 bp, spanning the entire VP1 sequence (891 nucleotides). A PrimeScript One Step RT-PCR Kit (TaKaRa, Dalian, China) was used for amplifying the VP1 region. The amplification conditions were as follows: reverse transcription at 50°C for 30 min, initial denaturation at 94°C for 2 min, followed by 32 cycles of denaturation at 94°C for 30 s, annealing at 50°C for 30 s, extension at 72°C for 80 s, and final extension at 72°C for 10 min to complete the amplification. All the PCR runs included the positive control and negative control to avoid false-positive results. All the primers were synthesized by Sangon Biotech (Shanghai, China). The amplified products (5 μL) were electrophoresed through 1.0% agarose gel in Tris-acetate-EDTA buffer and were identified according to the position corresponding to DNA molecular weight standards (Marker). The PCR products were purified by gel extraction and sequenced by Ruiboxingke Biotechnology Co., Ltd. (Beijing, China).

Phylogenetic analysis and determination of CVA16 genotypes

The resulting sequences were spliced and aligned using Sequencher 5.4.6 software; nucleotide and amino acid similarity analyses were performed using BioEdit software (version 7.2.5). The entire VP1 sequences of Taiyuan CVA16 strains were aligned with the reference strain worldwide using pairwise alignment in MEGA (version 11.0.11). A phylogenetic tree was constructed using the neighbor-joining method, and the reliability of the tree was evaluated using 1000 bootstrap replicates (Tamura et al., 2021). The reference sequences used for homology analysis and phylogenetic tree construction were obtained from the GenBank database of the National Center for Biotechnology Information. The reference sequences are shown in Table 1 .

Table 1.

Reference sequences used for plotting the phylogenetic tree in this study.

Strains Accession number Year Location Genotype
G10 U05876 1951 South Africa A
CVA-16/11/CHN/GZ/2018 MT119437 2018 Guangdong B1a
CA16/TH/MUMT-1/2017 MH879032 2017 Thailand B1a
CVA16/HVN17.120/Hai_Phong/VNM/2017 LC438268 2017 Vietnam B1a
2014-YT309-CVA16(B1a) KX586352 2014 Shandong B1a
S701/BJ/CHN/2010 MT553119 2010 Beijing B1a
1575-Yamagata-2010 AB634448 2010 Japan B1a
GS0363F/GS/CHN/2008 GQ429255 2008 Gansu B1a
520-03F/SD/CHN/2007 GQ429220 2007 Shandong B1a
CNS68762/SAR/06 AM292451 2006 Malaysia B1a
418/Toyama/2006 AB465402 2006 Japan B1a
05.194.4135 FJ868280 2005 Australia B1a
Siriraj07/TH/02Y95-2260 GQ184132AB634302 20051995 ThailandJapan B1aB1a
CVA16/JN049/CHN/2018 MK357099 2018 Shandong B1b
S5876/BJ/CHN/2018 MT553216 2018 Beijing B1b
MY2018-05-CVA16 MW179119 2018 Sichuan B1b
HLJ18-16/HLJ/North/CHN/2018-08-05 MT212012 2018 Heilongjiang B1b
SD2018-YT231-CVA16-VP1 MT859144 2018 Shandong B1b
CVA16-97_GD-CHN_2018-03 MW197349 2018 Guangdong B1b
CVA16/SDJN100/CHN/2017 MH160028 2017 Shandong B1b
SHCA2016-084 KX871438 2016 Shanghai B1b
QH16-8/QH/West/CHN/2016-07-07 MT212020 2016 Qinghai B1b
SHCA2016-112 KX871459 2016 Shanghai B1b
CVA16/Shenzhen97/CHN/2016 MH003970 2016 Guangdong B1b
CVA16/Shenzhen499/CHN/2015 MH003957 2015 Guangdong B1b
CVA16/HuB/C15/2014 KY100914 2014 Hubei B1b
C55-YN-CHN-2014 LC013399 2014 Yunnan B1b
752-Henan-2013 KM260103 2013 Henan B1b
998-Henan-2013 KM260082 2013 Henan B1b
16-Henan-2013 KM260120 2013 Henan B1b
GC13-049/NJ/CHN/2013 KP751473 2013 Jiangsu B1b
S1870/BJ/CHN/2013 MT553144 2013 Beijing B1b
12MM19_2012.05_JY KP341909 2012 Jiangsu B1b
SHCA2012-035 KX871273 2012 Shanghai B1b
E052(Suzhou/2012) MH491125 2012 Jiangsu B1b
11MF56_2011.08_JJ KP341818 2011 Jiangsu B1b
lianyungang-1-2011 KR138313 2011 Jiangsu B1b
Ningbo.CHN/113/2010 JQ315098 2010 Zhejiang B1b
MAS03/AH/CHN/2010 JQ409497 2010 Anhui B1b
QH0377T/QH/CHN/2008 GQ429271 2008 Qinghai B1b
BJ271 JF317967 2008 Beijing B1b
CF312044_FRA10 HE572997 2010 France B1c
CF341014_FRA10 HE573002 2010 France B1c
SB16087/SAR/05 AM292476 2005 Malaysia B1c
CVA-16/21/CHN/GZ/2018 MT119447 2018 Guangdong B1c
2680-Yamagata-2011 AB772007 2011 Japan B1c
SB2239/SAR/00 AM292468 2000 Malaysia B2
576/Toyama/1988 AB465368 1988 Japan B2
S10432/SAR/98 AM292455 1998 Malaysia B2
Y92-2861 AB634291 1992 Japan B2

Nucleotide sequence accession numbers

The nucleotide sequences used in this study were submitted in GenBank (https://www.ncbi.nlm.nih.gov/genbank/) under accession numbers OP373746-OP373967, which are shown in Supplementary Table S1 .

Results

Epidemiological features

From January 1, 2010 to December 31, 2021, a total of 71,158 HFMD cases were reported in Taiyuan City. Mild to moderate symptoms were present in the vast majority of cases (99.94%, 71116/71158); 42 cases were classified as severe and five of these died. The annual average incidence rate of HFMD was 123.69 cases per 100,000 individuals (range: 50.29–219.25 per 100,000 individuals). The patients included 42,515 males and 28,643 females, with a mean male-to-female sex ratio of 1.47:1 (range:1.26:1 to 1.64:1). The annual average incidence in males was 144.41 per 100,000 individuals and that in females was 101.20 per 100,000 individuals. Overall, males had a significantly higher prevalence of HFMD than that in females (χ² = 2188.249, P < 0.001). ( Table 2 )

Table 2.

Data of reported hand, foot, and mouth disease (HFMD) cases by gender, age group, and year.

Variable 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
HFMD Reported Cases
Mild cases 7177 8226 9278 4353 10108 7221 4472 7400 4647 4423 1100 2711
Severe cases 2 8 18 0 7 0 0 0 1 1 0 0
Deaths 1 1 2 0 1 0 0 0 0 0 0 0
Total (Incidence rate/105) 7180(170.76) 8235(190.20) 9298(209.27) 4353(95.80) 10116(219.25) 7221(153.00) 4472(92.17) 7400(148.49) 4648(90.87) 4424(84.56) 1100(20.68) 2711(50.29)
Gender
Male (Incidence rate/105) 4289(199.18) 4879(220.66) 5779(257.00) 2633(113.81) 5910(252.37) 4363(180.91) 2728(110.15) 4395(172.94) 2723(104.72) 2673(100.44) 633(23.19) 1510(54.86)
Female (Incidence rate/105) 2891(140.93) 3356(158.40) 3519(160.36) 1720(77.12) 4206(185.11) 2858(123.84) 1744(73.43) 3005(123.041) 1925(76.55) 1751(68.12) 467(18.04) 1201(45.52)
Gender ratio 1.48 1.45 1.64 1.53 1.41 1.53 1.56 1.46 1.41 1.53 1.36 1.26
Age Group (%)
<1 244(3.40%) 349(4.24%) 409(4.40%) 326(7.49%) 416(4.11%) 506(7.01%) 197(4.41%) 572(7.73%) 291(6.26%) 188(4.25%) 65(5.91%) 169(6.23%)
1-<2 1475(20.54%) 1643(19.95%) 2057(22.12%) 1234(28.35%) 2129(21.05%) 2033(28.15%) 915(20.46%) 1655(22.36%) 1135(24.42%) 786(17.77%) 204(18.55%) 610(22.50%)
2-<3 1453(20.24%) 1694(20.57%) 1824(19.62%) 778(17.87%) 1877(18.55%) 1312(18.17%) 810(18.11%) 1060(14.32%) 742(15.96%) 693(15.66%) 162(14.73%) 384(14.17%)
3-<4 1848(25.74%) 1997(24.25%) 2004(21.55%) 841(19.32%) 2273(22.47%) 1325(18.35%) 893(19.97%) 1620(21.89%) 760(16.35%) 910(20.57%) 244(22.18%) 414(15.27%)
4-<5 1090(15.18%) 1301(15.80%) 1439(15.48%) 563(12.93%) 1576(15.58%) 893(12.36%) 819(18.31%) 1110(15.00%) 711(15.30%) 623(14.08%) 169(15.36%) 439(16.19%)
5-<6 465(6.48%) 608(7.38%) 680(7.31%) 265(6.09%) 800(7.91%) 506(7.01%) 346(7.74%) 638(8.62%) 401(8.63%) 515(11.64%) 77(7.00%) 247(9.11%)
≧6 605(8.42%) 643(7.81%) 885(9.52%) 346(7.95%) 1045(10.33%) 646(8.95%) 492(11.00%) 745(10.07%) 608(13.08%) 709(16.03%) 179(16.27%) 448(16.53%)

From 2010 to 2021, most HFMD cases were observed in the age group of one to five years in Taiyuan, Shanxi Province [84.42% (60075/71158)], whereas incidence in children under one year of age (minimum age 1 day) was very low, and accounted for only 5.48%. Other details regarding age are shown in Table 2 . The highest percentage of severe and fatal cases was observed in the age group of one–three years.

Seasonal characteristics of HFMD

Except being affected by the COVID-19 epidemic in 2020, the monthly distribution of HFMD cases showed two epidemic peaks; the main peak was from May to August and the second peak was from October to December. HFMD epidemics were sporadic from January to March each year, and began to increase in April, with a major epidemic peak from May to August; they declined in September, followed by a secondary peak from October to December. And the peak of cases showed a slight but obvious shift from June before (including) 2016 to July since 2017. During the COVID-19 pandemic, an epidemic peak of HFMD was only observed from October to December in 2020, which accounted for 74.33% of the annual cases ( Figure 1 ).

Figure 1.

Figure 1

Monthly distribution of hand, foot, and mouth disease (HFMD) cases during 2010–2021 in Taiyuan.

Pathogen spectrum of HFMD

Enterovirus nucleic acid was detected using real-time reverse transcription polymerase chain reaction in 6641 clinical specimens collected from patients with HFMD from 2010–2021; overall, 4236 EV-positive specimens were detected, including 988(23.32%) EV-A71, 1488(35.13%) CVA16, and 1760(41.55%) other enteroviruses ( Table S2 ). The results showed that the two major pathogens causing HFMD before 2016 were EV-A71 and CVA16, although other EVs have also been reported. After 2016, HFMD cases caused by EV-A71 gradually decreased; however, CVA16 remains prevalent and has co-circulated with other EVs in Taiyuan ( Figure 2 ).

Figure 2.

Figure 2

Genotype of viruses causing hand, foot, and mouth disease during 2010–2021 in Taiyuan.

Phylogenetic analysis of CVA16 based on the VP1 sequence

To determine the genetic characteristics of CVA16 strains, we removed the identical sequences for the same month of the same year. Finally, a total of 273 CVA16 strains were used for phylogenetic analysis, including 222 CVA16 strains selected in this study and 51 other CVA16 reference strains obtained from GenBank. The 222 Taiyuan CVA16 strains in the phylogenetic tree were divided into two clades, belonging to the B1a and B1b evolutionary branches ( Figure 3A ). Among all strains, 184 were identified as subtype B1b and 38 as B1a. The 38 B1a strains were prevalent in 2010–2015 and in 2019–2021 ( Figure 3B ). The 184 B1b strains, were divided into two major prevalent branches, one prevalent in 2012–2019 and the other in 2016–2021; and the details of B1b are shown in Figure 3C , D .

Figure 3.

Figure 3

Phylogenetic analysis for subtyping 222 Coxsackievirus A16 (CVA16) strains in Taiyuan based on their VP1 sequences (A); CVA16 subtype B1a (B); CVA16 subtypes B1b-1, B1b-2 (C); and CVA16 subtypes B1b-3, B1b-4, B1b-5, B1b-6, B1b-7, B1b-8, and B1b-9 (D). Percentages of bootstrap values (1000 pseudo replicates) ≥ 80% are shown at the nodes. The CVA16 strains in Taiyuan are represented by triangles. Triangles of different colors represent different years. 2010 (Inline graphic) 2011 (Inline graphic) 2012 (Inline graphic) 2013 (Inline graphic) 2014 (Inline graphic) 2015 (Inline graphic) 2016 (Inline graphic) 2017 (Inline graphic) 2018 (Inline graphic) 2019 (Inline graphic) 2020 (Inline graphic) 2021(Inline graphic).

Upon calculating the similarities in nucleotides and amino acids, the sequences of 362 strains of CVA16 were found to have high similarity with each other; the nucleotide similarity was 86.5–100% and the amino acid similarity was 96.9–100%. Further, the CVA16 strains showed 74.2–77.2% and 90.9–92.2% similarity in the nucleotide and amino acid sequence with the CVA16 prototype strain (G10 strains), respectively. Thirty-eight B1a CVA16 strains shared 90.5–99.8% and 97.6–100% similarity in nucleotide and amino acid sequences, respectively, whereas 184 B1b CVA16 strains shared 90.6–99.8% and 97.9–100% similarity in the nucleotide and amino acid sequence, respectively.

Discussion

Based on the data from a twelve-year (2010–2021) surveillance of HFMD cases in Taiyuan city, our study provides a comprehensive landscape of the epidemiology of HFMD in Taiyuan City, Shanxi province, China. The results indicate that children aged 1–5 years accounted for most outbreaks, similar to reports from other regions in China and other countries (Chen et al., 2007; Momoki, 2009; Xing et al., 2014; Gui et al., 2015; Sun et al., 2017). These results suggest that children in this age group are at a high risk of enterovirus infection and should be targeted for HFMD control and prevention. More infections were found in males than in females. One explanation may be related to the extra outdoor activities by boys, including more frequent touching of unclean toys and facilities, which increases the level of exposure and the risk of the infection compared with that in girls. Further, the differential susceptibility of males and females at the level of host immune status, may also be responsible for this inconsistent sex ratio (Xing et al., 2014). Therefore, it is necessary to improve the hygiene status of children younger than 5 years of age to help reduce the risk of developing HFMD. Although HFMD cases have been reported throughout the year in Taiyuan City, the monthly distribution showed two peaks in HFMD epidemics, with the main peak between May and August, possibly because the virus spread is affected by increased activities of children during May and August of the year. The reason is unclear for the peak of HFMD cases shifted from before June 2016 (including 2016) to July 2017, it may be related to the sharp reduction in HFMD caused by EV-A71 following the introduction of the EV-A71 vaccine in 2016. A smaller peak occurs in November, probably because the cold season is conducive to the surviving of the virus. These results indicate epidemiological surveillance and prevention efforts should focus on the periods from May to August and from October to December.

Alternating outbreaks of CVA16 and EV-A71, considered to be main pathogens of HFMD, have occurred in East and Southeast Asia for more than 20 years (Li et al., 2005; Iwai et al., 2009). Outbreaks of HFMD with CVA16 have been reported in several cities in mainland China. However, long-term surveillance studies on CVA16 remain scarce (Zou et al., 2012; Zhu et al., 2013). In this 12-year surveillance study, the results showed an epidemic trend of both pathogens, from alternating with each other to CVA16 dominating over EV-A71. Before 2016, the two major pathogens causing HFMD were EV-A71 and CVA16, though other EVs have also been reported to cause HFMD. However, after administration of the EV-A71 inactivated vaccine, the pathogen spectrum of HFMD has changed to some extent, and the number of HFMD cases caused by EV-A71 has gradually decreased; however, CVA16 remains prevalent and has become one of the most important pathogens causing HFMD in Taiyuan City. Therefore, our study focused on the genetic characteristics of CVA16 to broaden our knowledge regarding this pathogen.

Numerous studies on CVA16 genotyping have shown that CVA16 can be divided into two genotypes: A and B (Perera et al., 2007; Zhang et al., 2010; Zhang et al., 2019). The prototype strain (G10/RSA/1951) is the only member of genotype A (Xu et al., 2018). Genotype B is divided into the subgenotypes B1 and B2, which are further divided into the evolutionary branches B1a, B1b, and B1c, and B2a, B2b, and B2c, respectively. Subgenotype B2 was first reported in Japan in 1981 and was not reported after 2000. Relatively, subgenotype B1 has been more common in recent HFMD outbreaks. CVA16 belonging to the evolutionary branches B1a and B1b were first isolated in 1995 and 1998, respectively, in Japan and became the predominant strains circulating globally since 2000. After 2000, subgenotype B1c was found in Malaysia, Russia, France, Japan, India, and other countries (Chen et al., 2013; Hassel et al., 2017; Gopalkrishna and Ganorkar, 2021). The first Chinese case of strain B1c (MT119447) was reported in Guangdong in 2018 (Xie et al., 2020).

In mainland China, most reported CVA16 strains belong to the B1a and B1b evolutionary branches (Chen et al., 2013). Our results showed that all CVA16 strains found in Taiyuan City belonged to the B1 subgenotype. Thirty-eight Taiyuan CVA16 strains belonged to the B1a evolutionary branch, responsible for two HFMD outbreaks being occurred from 2010 to 2015 and 2019 to 2021, respectively. This suggests that B1a disappeared after a period of prominence in Taiyuan City and became prevalent again in 2019. The other 184 Taiyuan CVA16 strains belonged to the B1b evolutionary branch, and were closely related to other domestic strains, such as Jiangsu, Henan, Shanghai, Shandong, and Guangdong. Except 2020, B1b was prevalent in other years. B1b was not detected in 2020; this may be attributed to the outbreak of COVID-19, which reduced the spread of viruses. The 184 strains belonging to the B1b evolutionary branch further showed two major prevalent branches, one in 2012–2019, and the other in 2016–2021. The remaining 21 B1b strains were prevalent in 2010–2014, 2016, and 2019. This indicated that although B1b was epidemic from 2010 to 2011, a new evolutionary branch appeared after 2012, which remained stable until 2019. During this period, new transmission chains emerged and have become prevalent since 2016. Thus, the two evolutionary branches of CVA16, B1a and B1b, coexisted and prevailed in Taiyuan from 2010 to 2021, with B1b as the dominant subtype. This observation is consistent with findings from other regions of China in recent years (Yin et al., 2014; Huang et al., 2015; Xia et al., 2016; Sun et al., 2017).

Our study has several limitations. First, the laboratory-confirmed cases in this study may have sampling bias, which may lead to further bias in our research results. Second, our study focused on the VP1 region of CVA16, which makes the genetic characterization imperfect; the further studies on the full-length genomic sequences of CVA16 are thus needed to illuminate the epidemiological and evolutionary dynamics of CVA16.

Conclusions

This study highlights the epidemiological characteristics of HFMD, and main pathogens of HFMD cases reported in Taiyuan City, Shanxi province from 2010 to 2021, focusing on the genetic characteristics of CVA16, as well as on the coexistence and propagation of the B1a and B1b evolutionary branches. These findings add to the available genetic resources on CVA16 worldwide. The surveillance and research results of enteroviruses in various places indicate that the epidemic trend of each type of enterovirus is changing and varies from place to place. Thus, the HFMD pathogen spectrum should be determined in a timely manner to provide a scientific basis for HFMD prevention, control, and early warning.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: GenBank (https://www.ncbi.nlm.nih.gov/genbank/) and the accession numbers are OP373746-OP373967.

Ethics statement

This study did not involve human participants or human experimentation. The human materials used were throat swabs, fecal swabs, herpes fluid, and cerebrospinal fluid collected from patients with HFMD for public health purposes. Specimens were analyzed after informed and verbal consent obtained from the parents or guardians of the children. This study was approved by the Institutional Review Board and Human Research Ethics Committee of the Taiyuan Center for Disease Control and Prevention, and the methods were carried out in accordance with the approved

Author contributions

JW and JG developed the original idea, drafted and reviewed the manuscript. YZ developed the original idea and contributed to the manuscript revision. ZC performed all the experiments, analyzed the data, and wrote the manuscript. HL engaged in the experimental operation and data analysis. JX, LZ and LG contributed to the specimens collection and provided technical support. ZZ, YS and ZH gathered and analyzed the patient data. All authors read and approved the final manuscript.

Funding

This study was supported by a Science and Technology research project of the Shanxi Provincial Department of Health (Project No. 201302026); National Key Research and Development Program of China (Project No. 2021YFC2302003), and Natural Science Foundation of Beijing (Project No. L192014).

Acknowledgments

The authors wish to thank county CDC employees in Taiyuan City who were responsible for the specimen collection process.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2022.1040414/full#supplementary-material

Supplementary Table 1

GenBank accession numbers assigned for all the CVA16-Taiyuan sequences based on entire VP1 region sequenced in this study.

Supplementary Table 2

Etiological composition of laboratory-detected HFMD cases in Taiyuan City, 2010-2021.

Abbreviations

HFMD, Hand, foot, and mouth disease; EV: Enterovirus; CVA16, Coxsackievirus A16; EV-A71, Enterovirus A71; CDC, Center for Disease Control and Prevention; Ct, Cycle threshold.

References

  1. Cai K., Wang Y., Guo Z., Yu H., Li H., Zhang L., et al. (2019). Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in shanghai, China. BMC Infect. Dis. 19 (1), 285. doi:  10.1186/s12879-019-3878-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chen S. C., Chang H. L., Yan T. R., Cheng Y. T., Chen K. T. (2007). An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am. J. Trop. Med. hyg. 77 (1), 188–191. doi: 10.4269/ajtmh.2007.77.188 [DOI] [PubMed] [Google Scholar]
  3. Chen M., He S., Yan Q., Xu X., Wu W., Ge S., et al. (2017). Severe hand, foot and mouth disease associated with coxsackievirus A10 infections in xiamen, China in 2015. J. Clin. Virol. 93, 20–24. doi:  10.1016/j.jcv.2017.05.011 [DOI] [PubMed] [Google Scholar]
  4. Chen X., Tan X., Li J., Jin Y., Gong L., Hong M., et al. (2013). Molecular epidemiology of coxsackievirus A16: intratype and prevalent intertype recombination identified. PloS One 8 (12), e82861. doi:  10.1371/journal.pone.0082861 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cox J. A., Hiscox J. A., Solomon T., Ooi M. H., Ng L. F. P. (2017). Immunopathogenesis and virus-host interactions of enterovirus 71 in patients with hand, foot and mouth disease. Front. Microbiol. 8. doi:  10.3389/fmicb.2017.02249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Esposito S., Principi N. (2018). Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur. J. Clin. Microbiol. Infect. Dis. 37 (3), 391–398. doi:  10.1007/s10096-018-3206-x [DOI] [PubMed] [Google Scholar]
  7. Gopalkrishna V., Ganorkar N. (2021). Epidemiological and molecular characteristics of circulating CVA16, CVA6 strains and genotype distribution in hand, foot and mouth disease cases in 2017 to 2018 from Western India. J. Med. Virol. 93 (6), 3572–3580. doi:  10.1002/jmv.26454 [DOI] [PubMed] [Google Scholar]
  8. Gui J., Liu Z., Zhang T., Hua Q., Jiang Z., Chen B., et al. (2015). Epidemiological characteristics and spatial-temporal clusters of hand, foot, and mouth disease in zhejiang province, China, 2008-2012. PloS One 10 (9), e0139109. doi:  10.1371/journal.pone.0139109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hassel C., Mirand A., Farkas A., Diedrich S., Huemer H. P., Peigue-Lafeuille H., et al. (2017). Phylogeography of coxsackievirus A16 reveals global transmission pathways and recent emergence and spread of a recombinant genogroup. J. Virol. 91 (18), e00630–17. doi:  10.1128/JVI.00630-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. He S., Chen M., Wu W., Yan Q., Zhuo Z., Su X., et al. (2018). An emerging and expanding clade accounts for the persistent outbreak of coxsackievirus A6-associated hand, foot, and mouth disease in China since 2013. Virology 518, 328–334. doi:  10.1016/j.virol.2018.03.012 [DOI] [PubMed] [Google Scholar]
  11. Hong J., Liu F., Qi H., Tu W., Ward M. P., Ren M., et al. (2022). Changing epidemiology of hand, foot, and mouth disease in China, 2013-2019: a population-based study. Lancet reg. Health West. Pacific 20, 100370. doi:  10.1016/j.lanwpc.2021.100370 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huang X., Wei H., Wu S., Du Y., Liu L., Su J., et al. (2015). Epidemiological and etiological characteristics of hand, foot, and mouth disease in henan, China, 2008-2013. Sci. Rep. 5, 8904. doi:  10.1038/srep08904 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Iwai M., Masaki A., Hasegawa S., Obara M., Horimoto E., Nakamura K., et al. (2009). Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in toyama, Japan between 1981 and 2007. Jpn J. Infect. Dis. 62 (4), 254–259. Available at: http://www.nih.go.jp/JJID/jjid.html [PubMed] [Google Scholar]
  14. Ji T., Han T., Tan X., Zhu S., Yan D., Yang Q., et al. (2019). Surveillance, epidemiology, and pathogen spectrum of hand, foot, and mouth disease in mainland of China from 2008 to 2017. Biosafety Health 1 (1), 32–40. doi:  10.1016/j.bsheal.2019.02.005 [DOI] [Google Scholar]
  15. Koh W. M., Badaruddin H., La H., Chen M. I., Cook A. R. (2018). Severity and burden of hand, foot and mouth disease in Asia: a modelling study. BMJ Glob. Health 3 (1), e000442. doi:  10.1136/bmjgh-2017-000442 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Li L., He Y., Yang H., Zhu J., Xu X., Dong J., et al. (2005). Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in shenzhen, people's republic of China. J. Clin. Microbiol. 43 (8), 3835–3839. doi:  10.1128/JCM.43.8.3835-3839.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. (2014). An inactivated enterovirus 71 vaccine in healthy children. N Engl. J. Med. 370 (9), 829–837. doi:  10.1056/NEJMoa1303224 [DOI] [PubMed] [Google Scholar]
  18. Lim C. T., Jiang L., Ma S., James L., Ang L. W. (2016). Basic reproduction number of coxsackievirus type A6 and A16 and enterovirus 71: estimates from outbreaks of hand, foot and mouth disease in Singapore, a tropical city-state. Epidemiol. Infect. 144 (5), 1028–1034. doi:  10.1017/S0950268815002137 [DOI] [PubMed] [Google Scholar]
  19. Li J. X., Song Y. F., Wang L., Zhang X. F., Hu Y. S., Hu Y. M., et al. (2016). Two-year efficacy and immunogenicity of sinovac enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev. Vaccines 15 (1), 129–137. doi:  10.1586/14760584.2016.1096782 [DOI] [PubMed] [Google Scholar]
  20. Momoki S. T. (2009). Surveillance of enterovirus infections in Yokohama city from 2004 to 2008. Japanese J. Infect. Dis. 62 (6), 471–473. [PubMed] [Google Scholar]
  21. Nhu L. N. T., Nhan L. N. T., Anh N. T., Hong N. T. T., Van H. M. T., Thanh T. T., et al. (2021). Coxsackievirus A16 in southern Vietnam. Front. Microbiol. 12. doi:  10.3389/fmicb.2021.689658 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Noisumdaeng P., Korkusol A., Prasertsopon J., Sangsiriwut K., Chokephaibulkit K., Mungaomklang A., et al. (2019). Longitudinal study on enterovirus A71 and coxsackievirus A16 genotype/subgenotype replacements in hand, foot and mouth disease patients in Thailand, 2000-2017. Int. J. Infect. Dis. 80, 84–91. doi:  10.1016/j.ijid.2018.12.020 [DOI] [PubMed] [Google Scholar]
  23. Perera D., Yusof M. A., Podin Y., Ooi M. H., Thao N. T., Wong K. K., et al. (2007). Molecular phylogeny of modern coxsackievirus A16. Arch. Virol. 152 (6), 1201–1208. doi:  10.1007/s00705-006-0934-5 [DOI] [PubMed] [Google Scholar]
  24. Sun Z., Zhang G., Guo P., Liu J., Gao Q., Xu X., et al. (2017). Epidemiological characterizations, pathogen spectrum and molecular characteristics of coxsackievirus A16 from patients with HFMD in yantai, Shandong, China between 2011 and 2015. Hum. Vaccines immunother. 13 (8), 1831–1838. doi:  10.1080/21645515.2017.1318233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Takahashi S., Liao Q., Van Boeckel T. P., Xing W., Sun J., Hsiao V. Y., et al. (2016). Hand, foot, and mouth disease in China: Modeling epidemic dynamics of enterovirus serotypes and implications for vaccination. PloS Med. 13 (2), e1001958. doi:  10.1371/journal.pmed.1001958 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tamura K., Stecher G., Kumar S. (2021). MEGA11: Molecular evolutionary genetics analysis version 11. Mol. Biol. Evol. 38 (7), 3022–3027. doi:  10.1093/molbev/msab120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tian H., Zhang Y., Sun Q., Zhu S., Li X., Pan Z., et al. (2014). Prevalence of multiple enteroviruses associated with hand, foot, and mouth disease in shijiazhuang city, hebei province, china: outbreaks of coxsackieviruses a10 and b3. PloS One 9 (1), e84233. doi:  10.1371/journal.pone.0084233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Van H. M. T., Anh N. T., Hong N. T. T., Nhu L. N. T., Nguyet L. A., Thanh T. T., et al. (2019). Enterovirus A71 phenotypes causing hand, foot and mouth disease, Vietnam. Emerg. Infect. Dis. 25 (4), 788–791. doi:  10.3201/eid2504.181367 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Xia Y., Shan J., Ji H., Zhang J., Yang H., Shen Q., et al. (2016). Study of the epidemiology and etiological characteristics of hand, foot, and mouth disease in suzhou city, East China, 2011-2014. Arch. Virol. 161 (7), 1933–1943. doi:  10.1007/s00705-016-2878-8 [DOI] [PubMed] [Google Scholar]
  30. Xie J., Yang X. H., Hu S. Q., Zhan W. L., Zhang C. B., Liu H., et al. (2020). Co-Circulation of coxsackieviruses a-6, a-10, and a-16 causes hand, foot, and mouth disease in guangzhou city, China. BMC Infect. Dis. 20 (1), 271. doi:  10.1186/s12879-020-04992-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J. T., et al. (2014). Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect. Dis. 14 (4), 308–318. doi:  10.1016/S1473-3099(13)70342-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Xu L., Cui D., Wang L., Cheng J., Sun C., Li L., et al. (2018). Genetic characteristics of the P1 coding region of coxsackievirus A16 associated with hand, foot, and mouth disease in China. Mol. Biol. Rep. 45 (6), 1947–1955. doi:  10.1007/s11033-018-4345-y [DOI] [PubMed] [Google Scholar]
  33. Yin D. Q., Wang C. B., Wang C. B., Xiao Z., Ji S. X. (2018). Epidemiology characteristics of human coxsackievirus A16 and enterovirus 71 circulating in linyi, China, from 2009 to 2017. Jpn J. Infect. Dis. 71 (6), 470–473. doi:  10.7883/yoken.JJID.2018.035 [DOI] [PubMed] [Google Scholar]
  34. Yin X. G., Yi H. X., Shu J., Wang X. J., Wu X. J., Yu L. H. (2014). Clinical and epidemiological characteristics of adult hand, foot, and mouth disease in northern zhejiang, China, may 2008-November 2013. BMC Infect. Dis. 14, 251. doi:  10.1186/1471-2334-14-251 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Zhang Y., Tan X. J., Wang H. Y., Yan D. M., Zhu S. L., Wang D. Y., et al. (2009). An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J. Clin. Virol. 44 (4), 262–267. doi:  10.1016/j.jcv.2009.02.002 [DOI] [PubMed] [Google Scholar]
  36. Zhang Y., Wang D., Yan D., Zhu S., Liu J., Wang H., et al. (2010). Molecular evidence of persistent epidemic and evolution of subgenotype B1 coxsackievirus A16-associated hand, foot, and mouth disease in China. J. Clin. Microbiol. 48 (2), 619–622. doi:  10.1128/JCM.02338-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Zhang Y., Xu W. B. (2013). Molecular epidemiology of enteroviruses associated with hand, foot, and mouth disease in the mainland of China. Biomed. Environ. sci.: BES 26 (11), 875–876. doi:  10.3967/bes2013.015 [DOI] [PubMed] [Google Scholar]
  38. Zhang M., Zhao Y., Zhang H., Lin K., Liu H., Zhang J., et al. (2019). Molecular characterization of coxsackievirus A16 strains isolated from children with severe hand, foot, and mouth disease in yunnan, southwest China, during 2009-2015. J. Med. Virol. 91 (1), 155–160. doi:  10.1002/jmv.25297 [DOI] [PubMed] [Google Scholar]
  39. Zhu J., Luo Z., Wang J., Xu Z., Chen H., Fan D., et al. (2013). Phylogenetic analysis of enterovirus 71 circulating in Beijing, China from 2007 to 2009. PloS One 8 (2), e56318. doi:  10.1371/journal.pone.0056318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Zou X. N., Zhang X. Z., Wang B., Qiu Y. T. (2012). Etiologic and epidemiologic analysis of hand, foot, and mouth disease in guangzhou city: a review of 4,753 cases. Braz. J. Infect. Dis. 16 (5), 457–465. doi:  10.1016/j.bjid.2012.08.001 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Table 1

GenBank accession numbers assigned for all the CVA16-Taiyuan sequences based on entire VP1 region sequenced in this study.

Supplementary Table 2

Etiological composition of laboratory-detected HFMD cases in Taiyuan City, 2010-2021.

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: GenBank (https://www.ncbi.nlm.nih.gov/genbank/) and the accession numbers are OP373746-OP373967.


Articles from Frontiers in Cellular and Infection Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES